VEGFA and breast cancer: Vascular endothelial growth factor (VEGF) is a key component of angiogenesis and the anti-VEGF antibody bevacizumab is widely used in clinical practice as an antiangiogenic agent for many types of cancers such as colorectal, lung, and breast cancer, as well as glioblastoma [1].